WO2024200769 - TREATMENT OF NEUROLOGICAL DISORDERS WITH ALLICIN AND ANALOGUES THEREOF
National phase entry:
Publication Number
WO/2024/200769
Publication Date
03.10.2024
International Application No.
PCT/EP2024/058682
International Filing Date
28.03.2024
Title **
[English]
TREATMENT OF NEUROLOGICAL DISORDERS WITH ALLICIN AND ANALOGUES THEREOF
[French]
TRAITEMENT DE TROUBLES NEUROLOGIQUES AVEC DE L'ALLICINE ET DES ANALOGUES ASSOCIÉS
Applicants **
KATHOLIEKE UNIVERSITEIT LEUVEN
STICHTING AMSTERDAM UMC
Inventors
DE WITTE, Peter
HEYLEN, Lise
LAGAE, Lieven
COPMANS, Daniëlle
NY, Annelii
ARONICA, Eleonora
MILLS, James
Priority Data
23164608.4
28.03.2023
EP
23177651.9
06.06.2023
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 1933 | |
| EPO | Filing, Examination, Granting | 8141 | |
| Japan | Filing, Examination, Granting | 1952 | |
| South Korea | Filing, Examination, Granting | 1656 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
18,422
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The invention relates to allicin and related compounds for use in the prevention or treatment of epilepsy.[French]
L'invention concerne de l'allicine et des composés apparentés destinés à être utilisés dans la prévention ou le traitement de l'épilepsie.